{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:15:27Z","timestamp":1793852127691,"version":"4.6.1"},"reference-count":227,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009965","name":"American College of Physicians","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009965","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.chest.2021.07.055","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T05:09:17Z","timestamp":1627880957000},"page":"e545-e608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1031,"title":["Antithrombotic Therapy for VTE Disease"],"prefix":"10.1016","volume":"160","author":[{"given":"Scott M.","family":"Stevens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Woller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Baumann","family":"Kreuziger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Bounameaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Doerschug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert-Jan","family":"Geersing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno V.","family":"Huisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Kearon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Knighton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Lake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Murin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine R.E.","family":"Vintch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip S.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Moores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.chest.2021.07.055_bib1","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"Andrews","year":"2013","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.chest.2021.07.055_bib2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2021.07.055_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1538-7836.2012.04629.x","article-title":"A\u00a0conceptual framework for two phases of anticoagulant treatment of venous thromboembolism","volume":"10","author":"Kearon","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2 suppl","key":"10.1016\/j.chest.2021.07.055_bib4","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2021.07.055_bib5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1016\/j.chest.2021.07.055_bib6","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib7","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/jth.12969","article-title":"Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH","volume":"13","author":"Barnes","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"issue":"7","key":"10.1016\/j.chest.2021.07.055_bib8","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/jth.13336","article-title":"Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH","volume":"14","author":"Kearon","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.chest.2021.07.055_bib9","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.chest.2021.07.055_bib10","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.chest.2021.07.055_bib11","doi-asserted-by":"crossref","first-page":"i2016","DOI":"10.1136\/bmj.i2016","article-title":"GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction","volume":"353","author":"Alonso-Coello","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.chest.2021.07.055_bib12","series-title":"GRADEpro GDT: GRADEpro Guideline Development Tool [software]","year":"2020"},{"issue":"7001","key":"10.1016\/j.chest.2021.07.055_bib13","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/bmj.311.7001.376","article-title":"Consensus methods for medical and health services research","volume":"311","author":"Jones","year":"1995","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.chest.2021.07.055_bib14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1378\/chest.14-0824","article-title":"Methodologies for the development of CHEST guidelines and expert panel reports","volume":"146","author":"Lewis","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.chest.2021.07.055_bib15","first-page":"CD013422","article-title":"Treatment of distal deep vein thrombosis","volume":"4","author":"Kirkilesis","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib16","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1378\/chest.14-0235","article-title":"The anticoagulation of calf thrombosis (ACT) project: results from the randomized controlled external pilot trial","volume":"146","author":"Horner","year":"2014","journal-title":"Chest"},{"issue":"8454","key":"10.1016\/j.chest.2021.07.055_bib17","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(85)90459-3","article-title":"Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis","volume":"2","author":"Lagerstedt","year":"1985","journal-title":"Lancet"},{"issue":"3-4","key":"10.1016\/j.chest.2021.07.055_bib18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0049-3848(94)90100-7","article-title":"Anticoagulant therapy in deep venous thrombosis: a randomized controlled study","volume":"73","author":"Nielsen","year":"1994","journal-title":"Thromb Res"},{"issue":"12","key":"10.1016\/j.chest.2021.07.055_bib19","doi-asserted-by":"crossref","first-page":"e556","DOI":"10.1016\/S2352-3026(16)30131-4","article-title":"Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial","volume":"3","author":"Righini","year":"2016","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.chest.2021.07.055_bib20","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jvs.2010.05.094","article-title":"Therapy of isolated calf muscle vein thrombosis: a randomized, controlled study","volume":"52","author":"Schwarz","year":"2010","journal-title":"J\u00a0Vasc Surg"},{"issue":"2 suppl","key":"10.1016\/j.chest.2021.07.055_bib21","doi-asserted-by":"crossref","first-page":"e351S","DOI":"10.1378\/chest.11-2299","article-title":"Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Bates","year":"2012","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib22","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/jth.13677","article-title":"Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis","volume":"15","author":"Franco","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"10.1016\/j.chest.2021.07.055_bib23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1076029611422363","article-title":"Diagnosis and management of isolated subsegmental pulmonary embolism: review and assessment of the options","volume":"18","author":"Stein","year":"2012","journal-title":"Clin Appl Thromb Hemost"},{"issue":"8","key":"10.1016\/j.chest.2021.07.055_bib24","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/j.1538-7836.2012.04804.x","article-title":"Symptomatic subsegmental pulmonary embolism: what is the next step?","volume":"10","author":"Carrier","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"issue":"7","key":"10.1016\/j.chest.2021.07.055_bib25","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood-2013-04-497545","article-title":"Risk profile and clinical outcome of symptomatic subsegmental acute pulmonary embolism","volume":"122","author":"den Exter","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.chest.2021.07.055_bib26","doi-asserted-by":"crossref","first-page":"f3368","DOI":"10.1136\/bmj.f3368","article-title":"When a test is too good: how CT pulmonary angiograms find pulmonary emboli that do not need to be found","volume":"347","author":"Wiener","year":"2013","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.chest.2021.07.055_bib27","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/j.1538-7836.2010.03938.x","article-title":"Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications: a systematic review and meta-analysis of the management outcome studies","volume":"8","author":"Carrier","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11239-015-1169-7","article-title":"Clinical significance and management of subsegmental pulmonary embolism","volume":"39","author":"Ikesaka","year":"2015","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"22","key":"10.1016\/j.chest.2021.07.055_bib29","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa052367","article-title":"Multidetector computed tomography for acute pulmonary embolism","volume":"354","author":"Stein","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib30","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.thromres.2010.03.016","article-title":"Prevalence and clinical history of incidental, asymptomatic pulmonary embolism: a meta-analysis","volume":"125","author":"Dentali","year":"2010","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.chest.2021.07.055_bib31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1538-7836.2010.04114.x","article-title":"Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning","volume":"9","author":"O\u2019Connell","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.chest.2021.07.055_bib32","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.thromres.2018.07.023","article-title":"The efficacy and safety of anticoagulation in cerebral vein thrombosis: a systematic review and meta-analysis","volume":"169","author":"Al Rawahi","year":"2018","journal-title":"Thromb Res"},{"issue":"8767","key":"10.1016\/j.chest.2021.07.055_bib33","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0140-6736(91)90607-Q","article-title":"Heparin treatment in sinus venous thrombosis","volume":"338","author":"Einhaupl","year":"1991","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib34","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/01.STR.30.3.484","article-title":"Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis","volume":"30","author":"de Bruijn","year":"1999","journal-title":"Stroke"},{"issue":"2","key":"10.1016\/j.chest.2021.07.055_bib35","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(07)70029-7","article-title":"Cerebral venous thrombosis: an update","volume":"6","author":"Bousser","year":"2007","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.chest.2021.07.055_bib36","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1161\/STROKEAHA.112.671453","article-title":"The incidence of cerebral venous thrombosis: a cross-sectional study","volume":"43","author":"Coutinho","year":"2012","journal-title":"Stroke"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib37","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1160\/TH09-12-0827","article-title":"Evidence and clinical judgment: treatment of cerebral vein thrombosis","volume":"103","author":"Ageno","year":"2010","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib38","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1161\/01.STR.30.3.481","article-title":"Cerebral venous thrombosis: nothing, heparin, or local thrombolysis?","volume":"30","author":"Bousser","year":"1999","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib39","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1161\/01.STR.30.3.489","article-title":"Cerebral venous thrombosis: combined intrathrombus rtPA and intravenous heparin","volume":"30","author":"Frey","year":"1999","journal-title":"Stroke"},{"issue":"2 suppl","key":"10.1016\/j.chest.2021.07.055_bib40","doi-asserted-by":"crossref","first-page":"e601S","DOI":"10.1378\/chest.11-2302","article-title":"Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Lansberg","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.chest.2021.07.055_bib41","first-page":"CD002783","article-title":"Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb","volume":"1","author":"Broderick","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"23","key":"10.1016\/j.chest.2021.07.055_bib42","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa1615066","article-title":"Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis","volume":"377","author":"Vedantham","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib43","first-page":"973","article-title":"Controlled study of thrombolytic therapy in deep vein thrombosis","volume":"74","author":"Tsapogas","year":"1973","journal-title":"Surgery"},{"issue":"12","key":"10.1016\/j.chest.2021.07.055_bib44","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/bjs.1800661203","article-title":"A\u00a0comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial","volume":"66","author":"Elliot","year":"1979","journal-title":"Br J Surg"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib45","first-page":"881","article-title":"Low dose systemic thrombolytic therapy for treatment of deep venous thrombosis","volume":"43","author":"Ugurlu","year":"2002","journal-title":"J\u00a0Cardiovasc Surg (Torino)"},{"issue":"1","key":"10.1016\/j.chest.2021.07.055_bib46","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0049-3848(89)90451-9","article-title":"Multicenter pilot study of the efficacy and safety of systemic rt-PA administration in the treatment of deep vein thrombosis of the lower extremities and\/or pelvis","volume":"55","author":"Verhaeghe","year":"1989","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.chest.2021.07.055_bib47","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/S0735-1097(00)00863-9","article-title":"Short- and long-term results after thrombolytic treatment of deep venous thrombosis","volume":"36","author":"Schweizer","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0002-9343(90)90148-7","article-title":"Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis","volume":"88","author":"Goldhaber","year":"1990","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.chest.2021.07.055_bib49","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.0954-6820.1986.tb03323.x","article-title":"Long-term sequelae of calf vein thrombosis treated with heparin or low-dose streptokinase","volume":"219","author":"Schulman","year":"1986","journal-title":"Acta Med Scand"},{"issue":"5","key":"10.1016\/j.chest.2021.07.055_bib50","first-page":"1018","article-title":"Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy","volume":"89","author":"Marder","year":"1977","journal-title":"J\u00a0Lab Clin Med"},{"issue":"2 Pt 1","key":"10.1016\/j.chest.2021.07.055_bib51","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0002-8703(96)90427-5","article-title":"Bolus recombinant urokinase versus heparin in deep venous thrombosis: a randomized controlled trial","volume":"132","author":"Goldhaber","year":"1996","journal-title":"Am Heart J"},{"issue":"4 suppl","key":"10.1016\/j.chest.2021.07.055_bib52","first-page":"172S","article-title":"Tissue plasminogen activator (rt-PA) vs\u00a0heparin in deep vein thrombosis: results of a randomized trial","volume":"97","author":"Turpie","year":"1990","journal-title":"Chest"},{"issue":"5647","key":"10.1016\/j.chest.2021.07.055_bib53","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.1.5647.806","article-title":"Treatment of deep vein thrombosis: a trial of heparin, streptokinase, and arvin","volume":"1","author":"Kakkar","year":"1969","journal-title":"Br Med J"},{"issue":"7","key":"10.1016\/j.chest.2021.07.055_bib54","first-page":"529","article-title":"Urokinase or heparin in the management of patients with deep vein thrombosis?","volume":"147","author":"Kiil","year":"1981","journal-title":"Acta Chir Scand"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib55","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.0954-6820.1978.tb14908.x","article-title":"A\u00a0prospective study of streptokinase and heparin in the treatment of deep vein thrombosis","volume":"203","author":"Arnesen","year":"1978","journal-title":"Acta Med Scand"},{"issue":"11","key":"10.1016\/j.chest.2021.07.055_bib56","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1177\/000331977602701105","article-title":"Deep vein thrombosis treated with streptokinase or heparin: follow-up of a randomized study","volume":"27","author":"Common","year":"1976","journal-title":"Angiology"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib57","first-page":"167","article-title":"Comparative results of thrombolysis treatment with rt-PA and urokinase: a pilot study","volume":"27","author":"Schweizer","year":"1998","journal-title":"Vasa"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib58","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/ejvs.2002.1665","article-title":"Early results of thrombolysis vs\u00a0anticoagulation in iliofemoral venous thrombosis: a randomised clinical trial","volume":"24","author":"Elsharawy","year":"2002","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"9810","key":"10.1016\/j.chest.2021.07.055_bib59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(11)61753-4","article-title":"Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial","volume":"379","author":"Enden","year":"2012","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.chest.2021.07.055_bib60","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S2352-3026(19)30209-1","article-title":"Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial","volume":"7","author":"Notten","year":"2020","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1016\/j.chest.2021.07.055_bib61","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/CIRCULATIONAHA.118.037425","article-title":"Endovascular thrombus removal for acute iliofemoral deep vein thrombosis","volume":"139","author":"Comerota","year":"2019","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.chest.2021.07.055_bib62","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/j.1538-7836.2009.03464.x","article-title":"Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency","volume":"7","author":"Enden","year":"2009","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"10.1016\/j.chest.2021.07.055_bib63","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.ahj.2007.07.010","article-title":"Catheter-directed Venous Thrombolysis in acute iliofemoral vein thrombosis\u2014the CaVenT study: rationale and design of a multicenter, randomized, controlled, clinical trial (NCT00251771)","volume":"154","author":"Enden","year":"2007","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.chest.2021.07.055_bib64","doi-asserted-by":"crossref","first-page":"17-24","DOI":"10.1016\/j.jvir.2012.09.023","article-title":"Determinants of early and long-term efficacy of catheter-directed thrombolysis in proximal deep vein thrombosis","volume":"24","author":"Haig","year":"2013","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib65","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/jth.12184","article-title":"Cost-effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis","volume":"11","author":"Enden","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.chest.2021.07.055_bib66","first-page":"CD002783","article-title":"Thrombolysis for acute deep vein thrombosis","volume":"11","author":"Watson","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.chest.2021.07.055_bib67","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1055\/s-0039-1677795","article-title":"Pharmacomechanical catheter-directed thrombolysis in acute femoral-popliteal deep vein thrombosis: analysis from a stratified randomized trial","volume":"119","author":"Kearon","year":"2019","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.chest.2021.07.055_bib68","first-page":"CD004437","article-title":"Thrombolytic therapy for pulmonary embolism","volume":"12","author":"Hao","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.chest.2021.07.055_bib69","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/MAJ.0b013e3181f1fc3e","article-title":"Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin","volume":"341","author":"Fasullo","year":"2011","journal-title":"Am J Med Sci"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib70","first-page":"104","article-title":"Thrombolytic-plus-Anticoagulant Therapy versus Anticoagulant-Alone Therapy in Submassive Pulmonary Thromboembolism (TVASPE study): a randomized clinical trial","volume":"9","author":"Taherkhani","year":"2014","journal-title":"J\u00a0Tehran Heart Cent"},{"issue":"8844","key":"10.1016\/j.chest.2021.07.055_bib71","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0140-6736(93)90274-K","article-title":"Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion","volume":"341","author":"Goldhaber","year":"1993","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.chest.2021.07.055_bib72","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.amjcard.2012.09.027","article-title":"Moderate pulmonary embolism treated with thrombolysis (from the \u201cMOPETT\u201d trial)","volume":"111","author":"Sharifi","year":"2013","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib73","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/j.thromres.2009.09.017","article-title":"Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism","volume":"125","author":"Becattini","year":"2010","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.chest.2021.07.055_bib75","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/jth.12521","article-title":"Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3\u00a0months: multicenter double-blind, placebo-controlled randomized trial","volume":"12","author":"Kline","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"15","key":"10.1016\/j.chest.2021.07.055_bib76","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa021274","article-title":"Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism","volume":"347","author":"Konstantinides","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib77","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/0735-1097(92)90002-5","article-title":"PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism: plasminogen activator Italian multicenter study 2","volume":"20","author":"Dalla-Volta","year":"1992","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib78","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1378\/chest.98.6.1473","article-title":"A\u00a0randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism","volume":"98","author":"Levine","year":"1990","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.chest.2021.07.055_bib79","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1161\/CIRCULATIONAHA.113.005544","article-title":"Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism","volume":"129","author":"Kucher","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib80","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF01062714","article-title":"Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial","volume":"2","author":"Jerjes-Sanchez","year":"1995","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib81","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.0954-6820.1978.tb14909.x","article-title":"A\u00a0controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism","volume":"203","author":"Ly","year":"1978","journal-title":"Acta Med Scand"},{"issue":"5904","key":"10.1016\/j.chest.2021.07.055_bib82","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/bmj.1.5904.343","article-title":"Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism","volume":"1","author":"Tibbutt","year":"1974","journal-title":"Br Med J"},{"issue":"1","key":"10.1016\/j.chest.2021.07.055_bib83","first-page":"42","article-title":"Streptokinase and heparin in the treatment of major pulmonary embolism: a randomised comparison","volume":"13","author":"Dotter","year":"1979","journal-title":"Vasc Endovasc Surg"},{"issue":"4","key":"10.1016\/j.chest.2021.07.055_bib84","first-page":"161","article-title":"Pulmonary embolism and the urokinase pulmonary embolism trial","volume":"59","author":"Wenger","year":"1970","journal-title":"J\u00a0Med Assoc Ga"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib85","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1378\/chest.97.3.528","article-title":"Tissue plasminogen activator for the treatment of acute pulmonary embolism: a collaborative study by the PIOPED Investigators","volume":"97","year":"1990","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib86","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000195517","article-title":"Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial","volume":"54","author":"Marini","year":"1988","journal-title":"Respiration"},{"issue":"15","key":"10.1016\/j.chest.2021.07.055_bib87","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa1302097","article-title":"Fibrinolysis for patients with intermediate-risk pulmonary embolism","volume":"370","author":"Meyer","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2021.07.055_bib88","first-page":"CD004437","article-title":"Thrombolytic therapy for pulmonary embolism","volume":"3","author":"Dong","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"14","key":"10.1016\/j.chest.2021.07.055_bib89","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1182\/blood-2014-08-559278","article-title":"The role of thrombolytic therapy in pulmonary embolism","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.chest.2021.07.055_bib90","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/eurheartj\/ehu218","article-title":"Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis","volume":"36","author":"Marti","year":"2015","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.chest.2021.07.055_bib91","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/jth.12608","article-title":"Impact of the efficacy of thrombolytic therapy on the mortality of patients with acute submassive pulmonary embolism: a meta-analysis","volume":"12","author":"Nakamura","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"23","key":"10.1016\/j.chest.2021.07.055_bib92","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2014.5990","article-title":"Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis","volume":"311","author":"Chatterjee","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib93","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.thromres.2014.10.004","article-title":"Thrombolysis in hemodynamically stable patients with acute pulmonary embolism: a meta-analysis","volume":"134","author":"Riera-Mestre","year":"2014","journal-title":"Thromb Res"},{"issue":"10","key":"10.1016\/j.chest.2021.07.055_bib94","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.jcin.2015.04.020","article-title":"A\u00a0prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism: the SEATTLE II study","volume":"8","author":"Piazza","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"issue":"7","key":"10.1016\/j.chest.2021.07.055_bib95","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jvir.2014.12.017","article-title":"Ultrasound-accelerated catheter-directed thrombolysis for acute submassive pulmonary embolism","volume":"26","author":"Bagla","year":"2015","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"2","key":"10.1016\/j.chest.2021.07.055_bib96","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.thromres.2011.05.014","article-title":"Catheter-directed ultrasound-accelerated thrombolysis for the treatment of acute pulmonary embolism","volume":"128","author":"Engelhardt","year":"2011","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.chest.2021.07.055_bib97","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1007\/s11239-020-02258-6","article-title":"Massive pulmonary embolism in patients with extreme bleeding risk: a case series on the successful use of ultrasound-assisted, catheter directed thrombolysis in a district general hospital","volume":"51","author":"He","year":"2021","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"9","key":"10.1016\/j.chest.2021.07.055_bib98","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.amjcard.2019.07.040","article-title":"Meta-analysis of catheter directed ultrasound assisted thrombolysis in pulmonary embolism","volume":"124","author":"Pei","year":"2019","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.chest.2021.07.055_bib99","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1161\/01.CIR.77.2.353","article-title":"Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism","volume":"77","author":"Verstraete","year":"1988","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.chest.2021.07.055_bib100","first-page":"e52","article-title":"Management of pulmonary embolism with rheolytic thrombectomy","volume":"18","author":"Ferrigno","year":"2011","journal-title":"Can Respir J"},{"issue":"11","key":"10.1016\/j.chest.2021.07.055_bib101","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jvir.2009.08.002","article-title":"Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques","volume":"20","author":"Kuo","year":"2009","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"2","key":"10.1016\/j.chest.2021.07.055_bib102","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1378\/chest.07-2846","article-title":"Catheter-directed embolectomy, fragmentation, and thrombolysis for the treatment of massive pulmonary embolism after failure of systemic thrombolysis","volume":"134","author":"Kuo","year":"2008","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2021.07.055_bib103","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jvs.2014.10.036","article-title":"Catheter-directed interventions for acute pulmonary embolism","volume":"61","author":"Avgerinos","year":"2015","journal-title":"J\u00a0Vasc Surg"},{"issue":"16","key":"10.1016\/j.chest.2021.07.055_bib104","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/CIR.0b013e318214914f","article-title":"Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension","volume":"123","author":"Jaff","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.chest.2021.07.055_bib105","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jvsv.2018.10.025","article-title":"Catheter-directed thrombolysis versus suction thrombectomy in the management of acute pulmonary embolism","volume":"7","author":"Avgerinos","year":"2019","journal-title":"J\u00a0Vasc Surg Venous Lymphat Disord"},{"issue":"16","key":"10.1016\/j.chest.2021.07.055_bib106","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jama.2015.3780","article-title":"Effect of a retrievable vena cava filter plus anticoagulation vs\u00a0anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial","volume":"313","author":"Mismetti","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.chest.2021.07.055_bib107","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.thromres.2018.03.014","article-title":"Systematic review of efficacy and safety of retrievable inferior vena caval filters","volume":"165","author":"Bikdeli","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.chest.2021.07.055_bib108","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.thromres.2017.02.013","article-title":"Indications, complications and outcomes of inferior vena cava filters: a retrospective study","volume":"153","author":"Wassef","year":"2017","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib109","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/CIRCULATIONAHA.104.512834","article-title":"Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Pr\u00e9vention du Risque d\u2019Embolie Pulmonaire par Interruption Cave) randomized study","volume":"112","year":"2005","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.chest.2021.07.055_bib110","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJM199802123380701","article-title":"A\u00a0clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis","volume":"338","author":"Decousus","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib111","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.amjmed.2013.11.003","article-title":"Vena cava filters in unstable elderly patients with acute pulmonary embolism","volume":"127","author":"Stein","year":"2014","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.chest.2021.07.055_bib112","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.amjmed.2011.05.025","article-title":"Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism","volume":"125","author":"Stein","year":"2012","journal-title":"Am J Med"},{"issue":"16","key":"10.1016\/j.chest.2021.07.055_bib113","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.jacc.2014.01.058","article-title":"Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk","volume":"63","author":"Muriel","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.chest.2021.07.055_bib114","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1001\/jamainternmed.2013.2725","article-title":"The inferior vena cava filter: how could a medical device be so well accepted without any evidence of efficacy?","volume":"173","author":"Prasad","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.chest.2021.07.055_bib115","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1160\/TH13-07-0601","article-title":"Medical literature, vena cava filters and evidence of efficacy: a descriptive review","volume":"111","author":"Girard","year":"2014","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.chest.2021.07.055_bib116","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/jth.13564","article-title":"Inferior vena cava filters","volume":"15","author":"Duffett","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"10.1016\/j.chest.2021.07.055_bib117","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.chest.2016.03.015","article-title":"Temporary inferior vena cava filters: how do we move forward?","volume":"149","author":"Arous","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.chest.2021.07.055_bib118","first-page":"CD010019","article-title":"Outpatient versus inpatient treatment for acute pulmonary embolism","volume":"3","author":"Yoo","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"9785","key":"10.1016\/j.chest.2021.07.055_bib119","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(11)60824-6","article-title":"Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial","volume":"378","author":"Aujesky","year":"2011","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.chest.2021.07.055_bib120","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/acem.13451","article-title":"Emergency department discharge of pulmonary embolus patients","volume":"25","author":"Frank Peacock","year":"2018","journal-title":"Acad Emerg Med"},{"issue":"1","key":"10.1016\/j.chest.2021.07.055_bib121","first-page":"191","article-title":"Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: rationale and design of the HoT-PE trial","volume":"116","author":"Barco","year":"2016","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.chest.2021.07.055_bib122","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.amjmed.2015.10.022","article-title":"Home treatment of deep venous thrombosis according to comorbid conditions","volume":"129","author":"Stein","year":"2016","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.chest.2021.07.055_bib123","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1177\/1076029615598222","article-title":"Home treatment of deep venous thrombosis in the era of new oral anticoagulants","volume":"21","author":"Stein","year":"2015","journal-title":"Clin Appl Thromb Hemost"},{"issue":"7","key":"10.1016\/j.chest.2021.07.055_bib124","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1538-7836.2010.03888.x","article-title":"The validation and reproducibility of the Pulmonary Embolism Severity Index","volume":"8","author":"Chan","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"15","key":"10.1016\/j.chest.2021.07.055_bib125","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archinternmed.2010.199","article-title":"Simplification of the Pulmonary Embolism Severity Index for prognostication in patients with acute symptomatic pulmonary embolism","volume":"170","author":"Jimenez","year":"2010","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib126","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1538-7836.2009.03725.x","article-title":"Pulmonary Embolism Severity Index and troponin testing for the selection of low-risk patients with acute symptomatic pulmonary embolism","volume":"8","author":"Moores","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"10.1016\/j.chest.2021.07.055_bib127","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/2049-6958-8-34","article-title":"Predictive value of troponins and simplified Pulmonary Embolism Severity Index in patients with normotensive pulmonary embolism","volume":"8","author":"Ozsu","year":"2013","journal-title":"Multidiscip Respir Med"},{"issue":"10","key":"10.1016\/j.chest.2021.07.055_bib128","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1111\/j.1538-7836.2011.04469.x","article-title":"The simplified Pulmonary Embolism Severity Index (PESI): validation of a clinical prognostic model for pulmonary embolism","volume":"9","author":"Righini","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"10.1016\/j.chest.2021.07.055_bib129","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1160\/TH12-07-0466","article-title":"Comparison of two methods for selection of out of hospital treatment in patients with acute pulmonary embolism","volume":"109","author":"Zondag","year":"2013","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.chest.2021.07.055_bib130","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1378\/chest.09-0608","article-title":"Troponin-based risk stratification of patients with acute nonmassive pulmonary embolism: systematic review and metaanalysis","volume":"136","author":"Jim\u00e9nez","year":"2009","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib131","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1183\/09031936.00211613","article-title":"Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism","volume":"43","author":"Lankeit","year":"2014","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib132","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1183\/09031936.00147813","article-title":"Computed tomography to assess risk of death in acute pulmonary embolism: a meta-analysis","volume":"43","author":"Becattini","year":"2014","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.chest.2021.07.055_bib133","doi-asserted-by":"crossref","first-page":"R103","DOI":"10.1186\/cc10119","article-title":"The prognostic value of markers of right ventricular dysfunction in pulmonary embolism: a meta-analysis","volume":"15","author":"Coutance","year":"2011","journal-title":"Crit Care"},{"issue":"5","key":"10.1016\/j.chest.2021.07.055_bib134","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1160\/TH11-06-0371","article-title":"Cardiac troponin testing and the simplified Pulmonary Embolism Severity Index: the SWIss Venous ThromboEmbolism Registry (SWIVTER)","volume":"106","author":"Spirk","year":"2011","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.chest.2021.07.055_bib135","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1378\/chest.11-1355","article-title":"A\u00a0strategy combining imaging and laboratory biomarkers in comparison with a simplified clinical score for risk stratification of patients with acute pulmonary embolism","volume":"141","author":"Lankeit","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2021.07.055_bib136","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.chest.2018.01.035","article-title":"Management of low-risk pulmonary embolism patients without hospitalization: the Low-Risk Pulmonary Embolism Prospective Management Study","volume":"154","author":"Bledsoe","year":"2018","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2021.07.055_bib137","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.thromres.2009.09.026","article-title":"Home treatment in pulmonary embolism","volume":"126","author":"Otero","year":"2010","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.chest.2021.07.055_bib138","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.thromres.2013.08.012","article-title":"Outpatient treatment of symptomatic pulmonary embolism: a systematic review and meta-analysis","volume":"132","author":"Piran","year":"2013","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.chest.2021.07.055_bib139","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.annemergmed.2012.05.041","article-title":"Can selected patients with newly diagnosed pulmonary embolism be safely treated without hospitalization? A systematic review","volume":"60","author":"Vinson","year":"2012","journal-title":"Ann Emerg Med"},{"issue":"1","key":"10.1016\/j.chest.2021.07.055_bib140","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1183\/09031936.00093712","article-title":"Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis","volume":"42","author":"Zondag","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2021.07.055_bib141","first-page":"CD010957","article-title":"Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism","volume":"12","author":"Robertson","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.chest.2021.07.055_bib142","first-page":"CD010956","article-title":"Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis","volume":"6","author":"Robertson","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"21","key":"10.1016\/j.chest.2021.07.055_bib143","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood.V118.21.205.205","article-title":"A\u00a0randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II) [abstract]","volume":"118","author":"Schulman","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib144","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1253\/circj.CJ-15-0195","article-title":"Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study)","volume":"79","author":"Nakamura","year":"2015","journal-title":"Circ J"},{"issue":"9","key":"10.1016\/j.chest.2021.07.055_bib145","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.chest.2021.07.055_bib146","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.chest.2021.07.055_bib147","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"B\u00fcller","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.chest.2021.07.055_bib148","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jama.2014.10538","article-title":"Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis","volume":"312","author":"Castellucci","year":"2014","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.chest.2021.07.055_bib149","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/1076029615595880","article-title":"Peripherally inserted central catheter-related vein thrombosis in patients with lung cancer","volume":"23","author":"Kang","year":"2017","journal-title":"Clin Appl Thromb Hemost"},{"issue":"15","key":"10.1016\/j.chest.2021.07.055_bib150","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2014-07-590323","article-title":"The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis","volume":"124","author":"Chai-Adisaksopha","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.chest.2021.07.055_bib151","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.thromres.2014.10.033","article-title":"Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention","volume":"135","author":"Wu","year":"2015","journal-title":"Thromb Res"},{"issue":"21","key":"10.1016\/j.chest.2021.07.055_bib152","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1161\/CIRCULATIONAHA.113.002332","article-title":"Management and outcomes of major bleeding during treatment with dabigatran or warfarin","volume":"128","author":"Majeed","year":"2013","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.chest.2021.07.055_bib153","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"Schulman","year":"2014","journal-title":"Circulation"},{"issue":"26","key":"10.1016\/j.chest.2021.07.055_bib154","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.chest.2021.07.055_bib155","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.chest.2021.07.055_bib156","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/j.gastro.2013.02.041","article-title":"New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis","volume":"145","author":"Holster","year":"2013","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.chest.2021.07.055_bib157","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.thromres.2014.06.020","article-title":"Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis","volume":"134","author":"Gomez-Outes","year":"2014","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib158","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jth.12485","article-title":"Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis","volume":"12","author":"van der Hulle","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"10.1016\/j.chest.2021.07.055_bib159","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11239-014-1102-5","article-title":"Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism","volume":"39","author":"Mantha","year":"2015","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib160","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.amjcard.2013.11.049","article-title":"Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran","volume":"113","author":"Bloom","year":"2014","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.chest.2021.07.055_bib161","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.amjcard.2014.11.039","article-title":"A\u00a0meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonists","volume":"115","author":"Touma","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.chest.2021.07.055_bib162","doi-asserted-by":"crossref","first-page":"h1857","DOI":"10.1136\/bmj.h1857","article-title":"Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study","volume":"350","author":"Abraham","year":"2015","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib163","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.thromres.2014.03.035","article-title":"Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism","volume":"133","author":"Kang","year":"2014","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.chest.2021.07.055_bib164","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/jth.14752","article-title":"Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D trial (SELECT-D: 12m)","volume":"18","author":"Marshall","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"7","key":"10.1016\/j.chest.2021.07.055_bib165","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.chest.2021.07.055_bib166","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1055\/s-0038-1668523","article-title":"Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio study","volume":"118","author":"Agnelli","year":"2018","journal-title":"Thromb Haemost"},{"issue":"24","key":"10.1016\/j.chest.2021.07.055_bib167","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.chest.2021.07.055_bib168","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2021.07.055_bib169","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.thromres.2019.01.016","article-title":"Clinical impact of direct oral anticoagulant measuring in a real-life setting","volume":"175","author":"Winther-Larsen","year":"2019","journal-title":"Thromb Res"},{"issue":"20","key":"10.1016\/j.chest.2021.07.055_bib170","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.chest.2021.07.055_bib171","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.chest.2021.07.055_bib172","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"7","key":"10.1016\/j.chest.2021.07.055_bib173","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1055\/s-0040-1712098","article-title":"Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis","volume":"120","author":"Giustozzi","year":"2020","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib174","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/rth2.12102","article-title":"Managing thrombosis in cancer patients","volume":"2","author":"Wang","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"8","key":"10.1016\/j.chest.2021.07.055_bib175","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.amjmed.2008.12.023","article-title":"Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome","volume":"122","author":"Hull","year":"2009","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.chest.2021.07.055_bib176","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs\u00a0warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.chest.2021.07.055_bib177","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.clinthera.2019.06.015","article-title":"Recurrent thrombosis with direct oral anticoagulants in antiphospholipid syndrome: a systematic literature review and meta-analysis","volume":"41","author":"Sanchez-Redondo","year":"2019","journal-title":"Clin Ther"},{"issue":"9","key":"10.1016\/j.chest.2021.07.055_bib178","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib179","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1177\/1358863X16668588","article-title":"Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: findings from RE-COVER\u00ae, RE-COVER\u2122 II, and RE-MEDY\u2122","volume":"21","author":"Goldhaber","year":"2016","journal-title":"Vasc Med"},{"issue":"13","key":"10.1016\/j.chest.2021.07.055_bib180","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs\u00a0warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.chest.2021.07.055_bib181","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"issue":"21","key":"10.1016\/j.chest.2021.07.055_bib182","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.chest.2021.07.055_bib183","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11239-015-1316-1","article-title":"Guidance for the evaluation and treatment of hereditary and acquired thrombophilia","volume":"41","author":"Stevens","year":"2016","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"9","key":"10.1016\/j.chest.2021.07.055_bib184","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1111\/jth.14935","article-title":"Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis","volume":"18","author":"Zuily","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"22","key":"10.1016\/j.chest.2021.07.055_bib185","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.2018.16623","article-title":"Treatment of lower extremity superficial thrombophlebitis","volume":"320","author":"Di Nisio","year":"2018","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.chest.2021.07.055_bib186","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1056\/NEJMoa0912072","article-title":"Fondaparinux for the treatment of superficial-vein thrombosis in the legs","volume":"363","author":"Decousus","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2021.07.055_bib187","first-page":"CD004982","article-title":"Treatment for superficial thrombophlebitis of the leg","volume":"2","author":"Di Nisio","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.chest.2021.07.055_bib188","doi-asserted-by":"crossref","first-page":"944-949","DOI":"10.1016\/S0741-5214(03)00607-4","article-title":"Factors predictive of venous thrombotic complications in patients with isolated superficial vein thrombosis","volume":"38","author":"Quenet","year":"2003","journal-title":"J\u00a0Vasc Surg"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib189","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2352-3026(17)30014-5","article-title":"Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial","volume":"4","author":"Beyer-Westendorf","year":"2017","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.chest.2021.07.055_bib190","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/asheducation-2017.1.223","article-title":"Controversies in venous thromboembolism: to treat or not to treat superficial vein thrombosis","volume":"2017","author":"Beyer-Westendorf","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib191","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1055\/s-0039-1677793","article-title":"Treatment of superficial vein thrombosis: a systematic review and meta-analysis","volume":"119","author":"Duffett","year":"2019","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.chest.2021.07.055_bib192","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00277-008-0626-1","article-title":"6 versus 30\u00a0months anticoagulation for recurrent venous thrombosis in patients with high factor VIII","volume":"88","author":"Eischer","year":"2009","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.chest.2021.07.055_bib193","first-page":"848-851","article-title":"Anticoagulation period in idiopathic venous thromboembolism: how long is enough?","volume":"25","author":"Farraj","year":"2004","journal-title":"Saudi Med J"},{"issue":"12","key":"10.1016\/j.chest.2021.07.055_bib194","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199903253401201","article-title":"A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.","volume":"340","author":"Kearon","year":"1999","journal-title":"N Engl J Med."},{"issue":"7","key":"10.1016\/j.chest.2021.07.055_bib195","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3324\/haematol.2018.210971","article-title":"Six months versus two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis: the PADIS-DVT randomized clinical trial","volume":"104","author":"Couturaud","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.chest.2021.07.055_bib196","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jama.2015.7046","article-title":"Six months vs\u00a0extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE randomized clinical trial","volume":"314","author":"Couturaud","year":"2015","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.chest.2021.07.055_bib197","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa035029","article-title":"Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism","volume":"348","author":"Ridker","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib198","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1056\/NEJM200107193450302","article-title":"Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis: Warfarin Optimal Duration Italian Trial Investigators","volume":"345","author":"Agnelli","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib199","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2008-01-131656","article-title":"Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study","volume":"112","author":"Siragusa","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib200","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199702063360601","article-title":"The duration of oral anticoagulant therapy after a second episode of venous thromboembolism: the Duration of Anticoagulation Trial Study Group","volume":"336","author":"Schulman","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.chest.2021.07.055_bib201","first-page":"606-611","article-title":"Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis","volume":"74","author":"Levine","year":"1995","journal-title":"Thromb Haemost"},{"issue":"8","key":"10.1016\/j.chest.2021.07.055_bib202","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.chest.2021.07.055_bib203","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7326\/0003-4819-139-1-200307010-00008","article-title":"Extended oral anticoagulant therapy after a first episode of pulmonary embolism","volume":"139","author":"Agnelli","year":"2003","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.chest.2021.07.055_bib204","doi-asserted-by":"crossref","first-page":"1901647","DOI":"10.1183\/13993003.01647-2019","volume":"54","author":"Konstantinides","year":"2019","journal-title":"Eur Respir J"},{"issue":"19","key":"10.1016\/j.chest.2021.07.055_bib205","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.chest.2021.07.055_bib206","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1001\/archinternmed.2010.367","article-title":"Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review","volume":"170","author":"Iorio","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.chest.2021.07.055_bib207","doi-asserted-by":"crossref","first-page":"d3036","DOI":"10.1136\/bmj.d3036","article-title":"Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants\u2019 data from seven trials","volume":"342","author":"Boutitie","year":"2011","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.chest.2021.07.055_bib208","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3324\/haematol.10516","article-title":"The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism: a prospective cohort study in 1,626 patients","volume":"92","author":"Prandoni","year":"2007","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.chest.2021.07.055_bib209","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1111\/j.1538-7836.2010.04022.x","article-title":"Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis","volume":"8","author":"Baglin","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib210","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/archinte.160.6.769","article-title":"Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors","volume":"160","author":"Hansson","year":"2000","journal-title":"Arch Intern Med"},{"issue":"18","key":"10.1016\/j.chest.2021.07.055_bib211","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa030104","article-title":"Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran","volume":"349","author":"Schulman","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"32","key":"10.1016\/j.chest.2021.07.055_bib212","doi-asserted-by":"crossref","first-page":"3607-3612","DOI":"10.1200\/JCO.2013.51.7433","article-title":"Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study","volume":"32","author":"Napolitano","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.chest.2021.07.055_bib213","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/jth.14156","article-title":"Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis","volume":"16","author":"Vasanthamohan","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"issue":"13","key":"10.1016\/j.chest.2021.07.055_bib214","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.chest.2021.07.055_bib215","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1161\/CIRCULATIONAHA.114.008828","article-title":"Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration","volume":"130","author":"Simes","year":"2014","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.chest.2021.07.055_bib216","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMe1701628","article-title":"Reduced-intensity rivaroxaban for the prevention of recurrent venous thromboembolism","volume":"376","author":"Crowther","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2021.07.055_bib217","first-page":"CD011088","article-title":"Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism","volume":"12","author":"Robertson","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"21","key":"10.1016\/j.chest.2021.07.055_bib218","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMoa1210384","article-title":"Low-dose aspirin for preventing recurrent venous thromboembolism","volume":"367","author":"Brighton","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.chest.2021.07.055_bib219","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1114238","article-title":"Aspirin for preventing the recurrence of venous thromboembolism","volume":"366","author":"Becattini","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2021.07.055_bib220","doi-asserted-by":"crossref","first-page":"f5133","DOI":"10.1136\/bmj.f5133","article-title":"Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis","volume":"347","author":"Castellucci","year":"2013","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib221","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.chest.2018.08.1059","article-title":"Health-care cost impact of continued anticoagulation with rivaroxaban vs\u00a0aspirin for prevention of recurrent symptomatic VTE in the EINSTEIN-CHOICE trial population","volume":"154","author":"Wells","year":"2018","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.chest.2021.07.055_bib222","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.thromres.2015.02.032","article-title":"Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: a network meta-analysis","volume":"135","author":"Sobieraj","year":"2015","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.chest.2021.07.055_bib223","doi-asserted-by":"crossref","first-page":"249","DOI":"10.7326\/0003-4819-141-4-200408170-00004","article-title":"Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial","volume":"141","author":"Prandoni","year":"2004","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.chest.2021.07.055_bib224","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/0268355514544781","article-title":"Impact of graduated compression stockings on the prevention of post-thrombotic syndrome: results of a randomized controlled trial","volume":"30","author":"Jayaraj","year":"2015","journal-title":"Phlebology"},{"issue":"9054","key":"10.1016\/j.chest.2021.07.055_bib225","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(96)12215-7","article-title":"Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis","volume":"349","author":"Brandjes","year":"1997","journal-title":"Lancet"},{"issue":"9920","key":"10.1016\/j.chest.2021.07.055_bib226","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0140-6736(13)61902-9","article-title":"Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial","volume":"383","author":"Kahn","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.chest.2021.07.055_bib227","first-page":"1137","article-title":"Graduated compression stockings to treat acute leg pain associated with proximal DVT: a randomised controlled trial","volume":"112","author":"Kahn","year":"2014","journal-title":"Thromb Haemost"},{"issue":"18","key":"10.1016\/j.chest.2021.07.055_bib228","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000000130","article-title":"The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association","volume":"130","author":"Kahn","year":"2014","journal-title":"Circulation"}],"updated-by":[{"DOI":"10.1016\/j.chest.2022.05.028","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000}}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369221015063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369221015063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:37:00Z","timestamp":1757925420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369221015063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":227,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0012369221015063"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2021.07.055","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic Therapy for VTE Disease","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2021.07.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}